• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
By STEPHEN GUILFOYLE
Oct 05, 2020 | 11:13 AM EDT
Stocks quotes in this article: MRK, SGEN, BMY, MYOK

What was it, a month ago? Not even. I looked it up.

I am referring to the Merck (MRK) deal or deals with Seattle Genetics (SGEN) . While Seattle Genetics remains an independent company in the wake of those agreements, Merck did become an investor in that firm at a premium while doing what larger pharmaceutical names always do when they need to. They buy potential growth when growth is tough to come by. In Merck's case, its increased exposure to the work that Seattle Genetics has been doing in fighting certain cancers.

Monday brings a different deal, involving different companies, but for similar purposes.

This morning, Bristol-Myers Squibb (BMY) moved toward expanding its cardiovascular portfolio through the announced acquisition of MyoKardia (MYOK) for $13.18 billion. For those of you keeping score, that's $225 per share (in cash).

MyoKardia stock closed at $139.60 on Friday.

Now, this is interesting. MyoKardia has long been a money-losing operation, and the losses mounted in 2019 (as well as beyond). One little thing, though. The company just completed a Phase 2 clinical study of new drug candidate Mavacamten. This drug targets patients with hypertrophic cardiomyopathy, which is a heart disease known to cause strokes, and cardiac failure.

The drug was recently dubbed a "breakthrough therapy" designation by the FDA. That potential is what Bristol-Myers is paying for.

Aggression

Keep in mind that Bristol-Myers acquired Celgene (maker of the cancer drug Revlimid) as recently as last November. Now you understand how aggressive Bristol-Myers is pursuing growth down this avenue.

The Celgene deal itself is expected to be somewhat accretive to financial performance in this, its first year, while synergies expand over three years. It also comes with a pipeline of developing medicines.

This newer MyoKardia deal, to be financed through cash and debt, is expected to close later this year -- so very soon. The deal with MyoKardia is expected to be slightly dilutive through 2022, and then accretive starting in 2023, so this is longer-term thinking.

Is It Too Much?

Define it? The money? At these rates, nobody seems to think so. Integrating MyoKardia before Bristol-Myers is done integrating Celgene? That's a risk.

Anyone on Wall Street who has been through a merger where there were expected synergies knows how well, or how poorly such deals can wind up. Then again, this is not Credit Suisse First Boston / Donaldson Lufkin Jenrette. Anyone with a memory can remember how contentious that was.

These deals have an obvious acquirer and an obvious subordinate and do not provide almost the same exact services to the same exact clients. Still, this is a risk in my opinion, but lack of growth may have been the alternative, or competition for this name from other big pharma names. That said, I will take aggression over inertia. Although this is expensive.

The Chart

BMY has clearly been in a basing pattern since early summer. The pivot is obvious, up at the $64 level. Support just as obvious, just above $56. Should that line hold, the stock is probably at least technically a buy at these prices.

I am currently not selling puts given the environment. That's a bit of shame because you can get paid roughly $2.50 to take on potential equity risk at the $55 level right now expiring in January.

That means that if you want to play this game, you probably have to buy stock. If one buys 100 shares, one could reduce the expense by selling a covered $65 January call to knock more than a buck off of the investment's net basis. If held for the full year, BMY will pay quarterly dividends of $0.45, yielding 3.1%. In other words, they'll knock another $1.80 off of that net basis for you.

Bottom Line

I don't think BMY is a bad investment at these prices, and that dividend may enhance one's book in this coming period of increased volatility. My feeling is that BMY has upside potential (price target) capped at around $76. Of course, first things first. The first target is simply hitting that pivot.

(Bristol-Myers Squibb and Seattle Genetics are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Guilfoyle was long MRK equity.

TAGS: Mergers and Acquisitions | Dividends | Investing | Markets | Stocks | Trading | Healthcare | Pharmaceuticals | U.S. Equity

More from Stocks

The Housing Market Is Hot and Home Depot Is Poised to Make New Highs

Bruce Kamich
Jan 26, 2021 10:05 AM EST

We're in the middle of one of the best housing markets ever as people upgrade to homes away from cities.

Could Johnson & Johnson Go Higher and Higher?

Ed Ponsi
Jan 26, 2021 10:00 AM EST

Will the vaccine will be a game changer? The charts are giving indications that J&J is ready to run.

Clorox Is Ready to Clean Up as the Downtrend Has Been Broken

Bruce Kamich
Jan 26, 2021 9:20 AM EST

Let's review the charts and indicators.

An Entertainment Giant and a Big Drugmaker Present Buy Setups

Carolyn Boroden
Jan 26, 2021 8:30 AM EST

The stocks of Walt Disney Co. and Pfizer seem to offer nice upside potential based on their technical patterns.

Boot Barn Is Kickin' It, but Wait for a Correction to Saddle Up

Bruce Kamich
Jan 26, 2021 8:07 AM EST

The indicators for the western apparel retailer are bullish, but prices are extended compared to the longer-term moving averages, so be cautious.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • 08:05 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/26/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 09:52 AM EST GARY BERMAN

    INDU/DIA 20 DMA

    Fibocall: The DIA has the 20 DMA @ 307.81 and w...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login